Explosive Pre-Market Intel to Skyrocket Your Portfolio!

You are receiving this newsletter as a subscriber to Premium Stock Alerts

Hello Part-time Trader…👋

Premium Stock Alerts is here with your pre-market cheat sheet. In today's issue, we delve into:

  • Fed's Latest Announcements: Understand the Federal Reserve's recent decisions and economic outlook, and how they might influence the markets.

  • Volume Anomalies: Identify stocks witnessing unusual trading volumes, pointing to potential opportunities or risks.

  • Top Pre-Market Movers: Identify early winners poised for a strong market opening.

  • Market Indices & Sector Overview: Get a snapshot of key market indices and sector performances to gauge the day's potential trends.

  • FDA Approvals & Upcoming Decisions: Keep an eye on the latest FDA approvals and crucial upcoming decisions affecting biotech and pharmaceutical stocks.

Now, let's dive into today's edition for a closer look at the insights and analysis that will shape your trading decisions.

Happening Today

✓ 09:00 AM ET – House Price Index (YoY) (Mar)

✓ 09:00 AM ET – S&P/CS HPI Composite - 20 s.a. (MoM) (Mar)

✓ 10:00 AM ET – 3 & 6 - Month Bill Auction

✓ 10:30 AM ET – Dallas Fed Mfg Business Index (May)

✓ 01:00 PM ET – M2 Money Supply (MoM)


The little-known AI stock you need to read about now...

Discover the AI pioneer 99% of investors have never heard of... but it's one of my top picks to own now. This company has been an AI pioneer since before anyone ever heard of ChatGPT. Its sustained high double-digit growth has analysts raising price targets. 

Discover this under-the-radar AI stock now, ahead of the crowd. 

Get the name - FREE.


US stock futures were mostly flat on Tuesday, with tech stocks outperforming ahead of an inflation report.



⬆️ 0.07



⬆️ 0.011%



⬆️ 0.99%


Market dips today, most sectors down with Real Estate hardest hit. Only bright spot is tech, up slightly..




Consumer Discretionary


0.75% 🟢

Consumer Staples


0.23% 🟢



0.13% 🟢



0.68% 🟢

Health Care


-0.31% 🔴



0.55% 🟢



0.88% 🟢

Real Estate


0.02% 🟢

Information Technology


1.13% 🟢

Communication Services


1.29% 🟢



0.99% 🟢


Only own the best: 7 stocks poised for greatness in 2024

The uncertainty rattling the markets is off the charts.

But according to one of America's leading tech investors, if you're looking to protect your portfolio from the chaos and even significantly grow it in 2024...

You need to own these 7 stocks.

Click for FREE report.

Unusual Volume

📈 Netcapital Inc (NCPL) jumped 10.13% to $0.19 on a whopping 191.35 million shares traded after it announced the entry into definitive agreements for the immediate exercise of certain outstanding Series A-2 warrants to purchase up to an aggregate of 14,320,000 shares of common stock of the Company originally issued in December 2023, having an exercise price of $0.25 per share, at a reduced exercise price of $0.155 per share.

📈 Investors went wild, sending Cue Health Inc (HLTH) stock declining -1.91% to $0.09 on a massive volume of 160.21 million shares.

📈 Abnormal activity shook Nuburu Inc (BURU), pushing it up 19.68% to $0.17 on a whopping 153.06 million shares traded.

📈 OneMedNet Corp. (ONMD) stock recently closed 56.46% upper at $2.30 on substantial volume of 136.21 million shares. This unusual activity came after company announced a greater than five (5)-fold expansion of its proprietary iRWD™ network and platform.

📈 Yoshitsu Co Ltd ADR (TKLF) increase by 31.58% in a single trading session, with abnormally high trading volume of 84.5 million shares.


The Next Nvidia?

Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia.

Few in the media are talking about this story yet... but in the next 6 months that's all they'll talk about.

Go here now for this breaking story.

Premarket Movers

Insmed Inc (INSM) grew over +130.64% at $49.76 in pre-market trading today. INSM announced positive topline results from the ASPEN study, a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis.

Gamestop Corporation (NYSE: GME) shares are trading up +22.11% at $23.2 at the time of writing. Company’s 52-week ranged between $9.95 to $64.83. Analysts have a consensus price target of $6.20. The videogame retailer revealed that it had raised over $900 million from selling its shares during the market rally earlier this month.

Pineapple Energy Inc (PEGY) stock soared +21.45% to $0.215 in the pre-market trading. PEGY announced recently that its New York-based subsidiary SUNation signed a 1.95-megawatt project. SUNation will begin work on this large-scale commercial installation in early July.

Pre Market Gainers

Pre Market Change

Pre Market Volume
































#1 gold stock to own in 2024 as gold crushes all-time highs

Gold is crushing all-time highs above US$2,400 an ounce. If you're ready to join the 2024 wealth-building, then check out this incredibly well-run small-cap gold firm that's advancing its flagship gold project in Idaho. But don't hesitate. This under-the-radar company has already confirmed millions of ounces of gold and is set to drill for millions more.

Learn more.

Important FDA 

Recently Announced

Abeona Therapeutics (ABEO): On April 22nd, Abeona received a Complete Response Letter (CRL) for their Pz-cel treatment for recessive dystrophic epidermolysis bullosa. This means the FDA requires further data before considering approval.

Novo Nordisk (NVO): On May 24th, an FDA panel voted against recommending approval for Awiqli (Insulin Icodec) for treating adult diabetes. This is a setback for Novo Nordisk, but not the end of the road for the drug.

Positive Development

Bristol-Myers Squibb (BMY): Breyanzi received a full approval on May 16th for treating relapsed or refractory follicular lymphoma. This provides a new treatment option for patients battling this specific type of cancer.

Upcoming Announcements

Daiichi Sankyo & AstraZeneca (AZN.L, AZN): A verdict is expected on May 30th regarding the expanded use of Enhertu for treating adult patients with specific HER2-positive tumors. Both companies will be waiting anxiously to see if the FDA approves this broader application.

🎁 Looking for More? Check out these complementary newsletters for diverse perspectives:

Market BriefingGet the briefing Wall Street & C-Suites are reading.

Happy investing,

Maeve Grace
Editor In Chief
Premium Trade Alerts

Important: This newsletter does not provide investment advice. The stocks mentioned should not be taken as recommendations. Your investments are solely your decisions.

Disclosure: I hold no positions in any companies mentioned, either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article.

Join the conversation

or to participate.